Key points are not available for this paper at this time.
INTRODUCTION: F-FDG, plays a vital role in staging, detecting metastases, and assessing treatment response. This review explores the role of PET/CT in BC management and emerging radiotracers for enhanced diagnosis. A comprehensive literature search was conducted in PubMed and Scopus, covering studies from January 2000 to March 2025. AREAS COVERED: F-FDG in specific settings. Additionally, theranostic approaches are highlighted, offering personalized treatment based on molecular profiles. EXPERT OPINION: We recommend that physicians incorporate pathological analysis, including histopathological type, grade, and molecular status, when selecting the most appropriate radiotracer for BC diagnostics and treatment. Further research and clinical trials on emerging tracers and theranostic agents are essential to confirm their efficacy and safety.
Moghrabi et al. (Wed,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: